Mobile HIV and Addiction Clinics Linked to Fewer Deaths

What did the mobile HIV and addiction care trial find?

The HPTN 094 trial enrolled adults without HIV who injected drugs, had opioid use disorder, and were not receiving medication for that disorder at enrollment. Participants were willing to consider treatment. One group received mobile clinical services plus peer navigation; the comparison group received peer navigation connecting them with existing community services. Both approaches provided support rather than leaving participants without assistance. [NIH trial announcement](https://www.nih.gov/news-events/news-releases/integrated-health-service-delivery-through-medical-mobile-units-helped-reduce-deaths-among-individuals-risk-hiv-who-also-inject-drugs).

NIH reported a 71% relative reduction in deaths from all causes with the mobile approach. That figure is not a 71-percentage-point improvement in survival. The finding concerned a secondary outcome; the trial did not demonstrate superiority on its primary medication-use outcomes. [Published trial](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2855932).

Why might mobile clinics help when medication uptake remains low?

The mobile intervention combined HIV pre-exposure prophylaxis, or PrEP, medication for opioid use disorder, and limited clinical and supportive services. Housing instability, stigma, and disconnected health services can make attending appointments and sustaining treatment difficult. Offering several services together could reduce those obstacles, although this remains an interpretation of how the model might work. [NIH explanation of the intervention](https://www.nih.gov/news-events/news-releases/integrated-health-service-delivery-through-medical-mobile-units-helped-reduce-deaths-among-individuals-risk-hiv-who-also-inject-drugs).

Researchers found significantly lower mortality by 52 weeks, but emphasized that the result needs replication. It does not establish that mobile clinics prevented HIV infections or that any particular medicine produced the survival difference. Future evaluations should examine which elements of care matter, how consistently people receive them, and whether similar results occur elsewhere. [Trial findings and limitations](https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2855932).

What does this mean for people seeking HIV prevention?

PrEP helps prevent HIV in people who do not have the virus. CDC identifies sharing injection equipment or having an injection partner with HIV as reasons to discuss PrEP. Starting treatment requires HIV testing, and continued protection depends on taking the prescribed regimen and attending follow-up visits. Low uptake in a service-delivery trial does not mean the medicine itself is ineffective. [CDC guidance on PrEP](https://www.cdc.gov/hiv/prevention/prep.html).

Prevention also requires practical access to sterile equipment. CDC describes syringe services programs and pharmacies as routes to sterile syringes and other prevention services. A useful care plan can connect HIV testing, prevention medication, and substance use treatment instead of requiring patients to navigate each separately. Mobile clinics are one potential delivery route; the services available locally will determine what a person can access. [CDC information on prevention among people who inject drugs](https://cdc.gov/hiv-data/nhbs/hiv-risk-prevention-testing-pwid.html).